A novel pill helped people with advanced pancreatic cancer live longer, researchers reported Sunday, raising hopes of long-needed better treatments for one of the deadliest types of cancer.

A novel pill helped people with advanced pancreatic cancer live longer, researchers reported Sunday, raising hopes of long-needed better treatments for one of the deadliest types of cancer.

A novel pill helped people with advanced pancreatic cancer live longer, researchers reported Sunday.

New research shows a novel pill is helping people with advanced pancreatic cancer live longer.

A novel pill helped people with advanced pancreatic cancer live longer, researchers reported Sunday, raising hopes of long-needed better treatments for one of the deadliest types of cancer. “While not curing the cancer, it is a very large step forward,” said Dr. Zev Wainberg, of the University of California, Los…

An experimental pancreatic cancer pill, daraxonrasib, has shown to double survival rates and improve quality of life compared to chemotherapy. Read more at straitstimes.com. Read more at straitstimes.com.

An experimental pancreatic cancer pill, daraxonrasib, has shown to double survival rates and improve quality of life compared to chemotherapy. Read more at straitstimes.com. Read more at straitstimes.com.

At the ASCO annual meeting, Dana-Farber's Brian Wolpin, MD, MPH, will present positive results from the RASolute 302 trial showing a substantial prolongation of survival for patients with previously treated metastatic pancreatic cancer, regardless of RAS mutation status, taking daraxonrasib, an investigational oral RAS(ON) multi-selective inhibitor, compared with chemotherapy.